bosentan   Click here for help

GtoPdb Ligand ID: 3494

Synonyms: RO 47-0203 | Tracleer®
Approved drug PDB Ligand
bosentan is an approved drug (FDA (2001), EMA (2002))
Compound class: Synthetic organic
Comment: Bosentan is an endothelin receptor antagonist.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: bosentan

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 154.03
Molecular weight 551.18
XLogP 3.85
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCCOc1nc(nc(c1Oc1ccccc1OC)NS(=O)(=O)c1ccc(cc1)C(C)(C)C)c1ncccn1
Isomeric SMILES OCCOc1nc(nc(c1Oc1ccccc1OC)NS(=O)(=O)c1ccc(cc1)C(C)(C)C)c1ncccn1
InChI InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)
InChI Key GJPICJJJRGTNOD-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Used in the treatment of pulmonary arterial hypertension (PAH), believed to be caused by elevated endothelin levels. In September 2017, the FDA granted pediatric approval, allowing the use of bosentan treatment of PAH in patients ≥ 3 years of age.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Bosentan blocks the binding of endothelin to its receptors (ETA and ETB) in endothelium and vascular smooth muscle, thereby negating endothelin's deleterious vasoconstrictive and hypertensive effects.